AI-generated analysis. Always verify with the original filing.
AstraZeneca announced that the EMERALD-3 Phase III trial demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for Imfinzi plus Imjudo combined with lenvatinib and TACE in early liver cancer.
AstraZeneca reported positive high-level results from the EMERALD-3 Phase III trial, marking a significant advancement in the treatment of embolisation-eligible unresectable hepatocellular carcinoma (HCC). The trial evaluated the STRIDE regimen (Imfinzi plus Imjudo) combined with lenvatinib and transarterial chemoembolisation (TACE) against TACE alone. The primary endpoint of progression-free survival (PFS) was met with statistical significance and clinical meaningfulness. At interim analysis, a trend toward improved overall survival (OS) was observed for the combination arm. Additionally, the arm evaluating the STRIDE regimen plus TACE (without lenvatinib) showed strong trends toward improved PFS and OS, though not formally tested yet. The safety profile remained consistent with known data, and no new safety signals were identified. These results build on the HIMALAYA Phase III trial data, reinforcing the benefit of the STRIDE regimen in liver cancer. The company is engaging with global regulatory authorities regarding these data.